Updates

Dechra Pharmaceuticals

November 2008

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Dechra Pharmcaceuticals, which we highlighted in August, has announced a strong set of final results. For the year to 30 June turnover was up 20% to Â£304m while pretax profit increased 33% to Â£16.9m. Eps rose 23% to 20.8p. Both divisions performed creditably with NVS, the wholesale distributor of pharmaceuticals and pet products, increasing sales by 10.5%. Meanwhile, the specialist pharmaceutical division, which provides own-branded veterinary products to the companion animal market, grew sales 32% mainly thanks to Vetoryl (for Cushings Disease in dogs) and Felimazole (hyperthyroidism in older cats). Shore Capital has raised its eps forecasts to 24p for this year, with 29p expected the following year, although ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Afren - Production to hit 21,000 bopd by November

TMI Trader Portfolio - November '08

Dechra Pharmaceuticals (November 2010)

Dechra Pharmaceuticals - US launch of Vetoryl to boost profits (February 2010)

Dechra Pharmaceuticals - US blockbuster potential for key drug (August 2008)

Dechra Pharmaceuticals - Impending US drug approval could herald profit surge (April 2007)

Dechra Pharmaceuticals - Gains approach Â£1 per share (November 2005)

Dechra Pharmaceuticals (April 2005)

Dechra Pharmaceuticals - Positive AGM (December 2004)

Dechra Pharmaceuticals - New animal drug could be blockbuster (October 2004)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X